Ivabradina Viatris (Ivabradine Oxalate)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the natural pacemaker of the heart. By inhibiting this inward sodium/potassium current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a reduced heart rate without decreasing the strength of cardiac contraction.

The exact dose of Ivabradina Viatris is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerance. Physicians typically start with a low dose and titrate upward as needed, following local prescribing guidelines.

The safety of ivabradine in pregnancy and lactation has not been established, and the product carries an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and a healthcare professional should be consulted.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated or not tolerated. Beta‑blockers also provide additional anti‑adrenergic effects, so the choice depends on the patient’s overall cardiovascular profile and comorbidities.

Ivabradina Viatris should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water and not crushed or chewed, to ensure proper absorption and effect.

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances that may lead to permanent vision loss. Patients should be monitored regularly for heart‑rate changes and any new visual symptoms, and therapy should be stopped if serious adverse events occur.

Ivabradina Viatris is contraindicated in patients with severe hypotension, sick‑sinus syndrome, second‑ or third‑degree atrioventricular block (unless a pacemaker is in place), acute decompensated heart failure, and in those who are unable to monitor their heart rate reliably. It should also be avoided in individuals with known hypersensitivity to ivabradine.